We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current SNW market cap is 134.13B. The company's latest EPS is EUR 4.4386 and P/E is 24.21.
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 36.04B | 37.76B | 43B | 43.07B | 46.11B |
| Operating Income | 6.42B | 7.71B | 10B | 7.19B | 7.02B |
| Net Income | 12.29B | 6.22B | 8.37B | 5.4B | 5.56B |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 114.41B | 120.24B | 126.72B | 126.46B | 132.8B |
| Total Liabilities | 51.16B | 51.21B | 51.57B | 52.11B | 54.94B |
| Total Equity | 63.25B | 69.03B | 75.15B | 74.35B | 77.86B |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | 7.42B | 10.52B | 10.53B | 10.26B | 9.08B |
| Investing | 3.62B | -7.3B | -2.08B | -6.2B | -4.41B |
| Financing | -6.49B | -7.06B | -5.82B | -8.05B | -5.76B |
| Market Cap | 134.13B |
| Price to Earnings Ratio | 24.21 |
| Price to Sales Ratio | 2.92 |
| Price to Cash Ratio | 18.09 |
| Price to Book Ratio | 1.73 |
| Dividend Yield | 3.51% |
| Shares Outstanding | 1.25B |
| Average Volume (1 week) | 5.67k |
| Average Volume (1 Month) | 4.98k |
| 52 Week Change | 21.56% |
| 52 Week High | 110.86 |
| 52 Week Low | 85.09 |
| Spread (Intraday) | 0.26 (0.24%) |
| Company Name | Sanofi |
| Address |
46, avenue de la grande armee paris, paris 75017 |
| Website | https://www.sanofi.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
